120 related articles for article (PubMed ID: 20423925)
1. A general inefficacy interim monitoring rule for randomized clinical trials.
Freidlin B; Korn EL; Gray R
Clin Trials; 2010 Jun; 7(3):197-208. PubMed ID: 20423925
[TBL] [Abstract][Full Text] [Related]
2. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
3. Comparison of futility monitoring guidelines using completed phase III oncology trials.
Zhang Q; Freidlin B; Korn EL; Halabi S; Mandrekar S; Dignam JJ
Clin Trials; 2017 Feb; 14(1):48-58. PubMed ID: 27590208
[TBL] [Abstract][Full Text] [Related]
4. Inefficacy interim monitoring procedures in randomized clinical trials: the need to report.
Korn EL; Freidlin B
Am J Bioeth; 2011 Mar; 11(3):2-10. PubMed ID: 21400374
[TBL] [Abstract][Full Text] [Related]
5. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
Zhao Y; Grambsch PM; Neaton JD
Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
[TBL] [Abstract][Full Text] [Related]
6. [Controlled randomized clinical trials].
Jaillon P
Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
[TBL] [Abstract][Full Text] [Related]
7. Information time scales for interim analyses of randomized clinical trials.
Freidlin B; Othus M; Korn EL
Clin Trials; 2016 Aug; 13(4):391-9. PubMed ID: 27136947
[TBL] [Abstract][Full Text] [Related]
8. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
Johnson VE; Cook JD
Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131
[TBL] [Abstract][Full Text] [Related]
9. Failsafe automation of Phase II clinical trial interim monitoring for stopping rules.
Day RS
Clin Trials; 2010 Feb; 7(1):78-84. PubMed ID: 20156959
[TBL] [Abstract][Full Text] [Related]
10. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
Lachin JM
Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
[TBL] [Abstract][Full Text] [Related]
11. A flexible design for multiple armed screening trials.
Sargent DJ; Goldberg RM
Stat Med; 2001 Apr; 20(7):1051-60. PubMed ID: 11276035
[TBL] [Abstract][Full Text] [Related]
12. Frequentist evaluation of group sequential clinical trial designs.
Emerson SS; Kittelson JM; Gillen DL
Stat Med; 2007 Dec; 26(28):5047-80. PubMed ID: 17573678
[TBL] [Abstract][Full Text] [Related]
13. Hybridization of conditional and predictive power for futility assessment in sequential clinical trials with time-to-event outcomes: a resampling approach.
Yi J; Fang L; Su Z
Contemp Clin Trials; 2012 Jan; 33(1):138-42. PubMed ID: 21983624
[TBL] [Abstract][Full Text] [Related]
14. Stopping clinical trials early for benefit: impact on estimation.
Freidlin B; Korn EL
Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials.
Bennett CL; George SL; Vose JM; Nemunaitis JJ; Armitage JL; Armitage JO; Gorin NC; Gulati SC
Stem Cells; 1995 Jul; 13(4):414-20. PubMed ID: 7549900
[TBL] [Abstract][Full Text] [Related]
16. A standardization method to adjust for the effect of patient selection in phase II clinical trials.
Mazumdar M; Fazzari M; Panageas KS
Stat Med; 2001 Mar; 20(6):883-92. PubMed ID: 11252010
[TBL] [Abstract][Full Text] [Related]
17. Sequential urn designs with elimination for comparing K > or =3 treatments.
Coad DS; Ivanova A
Stat Med; 2005 Jul; 24(13):1995-2009. PubMed ID: 15803441
[TBL] [Abstract][Full Text] [Related]
18. Group sequential and adaptive designs: a novel, promising tool for nursing research.
Baldi I; Gouchon SM; Di Giulio P; Buja A; Gregori D
J Adv Nurs; 2011 Aug; 67(8):1824-33. PubMed ID: 21517937
[TBL] [Abstract][Full Text] [Related]
19. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
Lunsford LD; Flickinger JC; Larson D
Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
[TBL] [Abstract][Full Text] [Related]
20. A flexible futility monitoring method with time-varying conditional power boundary.
Ying Zhang ; Clarke WR
Clin Trials; 2010 Jun; 7(3):209-18. PubMed ID: 20423927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
